Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

PegBio 派格生物 Pre-IPO: R&D Deceleration

PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal

PegBio (派格生物) IPO: Thoughts on Valuation

PegBio 派格生物 IPO: A (Supposedly) Straightforward GLP-1 Challenger Story

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>PegBio is looking at raising up to USD 100m to list in Hong Kong.</li>
<li>We have previously covered the company’s fundamentals and a brief valuation.</li>
<li>We look at the difference between previous filing and current PHIP filing. We see massive delays which don’t position the company well for the listing.</li>
</ul>


PegBio is looking at raising up to USD 100m to list in Hong Kong.
We have previously covered the company’s fundamentals and a brief valuation.
We look at the difference between previous filing and current PHIP filing. We see massive delays which don’t position the company well for the listing.


PegBio 派格生物 IPO: PHIP Updates Don’t Look Good